Valuation: Exelixis, Inc.

Market Cap 12.54B 10.83B 10.18B 9.26B 17.4B 1,199B 17.69B 119B 46.63B 600B 47.08B 46.06B 1,995B P/E 2026 *
15.7x
P/E 2027 * 13.5x
Enterprise Value 11.8B 10.19B 9.57B 8.71B 16.37B 1,128B 16.64B 112B 43.86B 565B 44.29B 43.33B 1,877B EV / Sales 2026 *
4.62x
EV / Sales 2027 * 3.8x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day+0.24%
1 week-6.29%
Current month-4.45%
1 month-9.14%
3 months-0.84%
6 months+14.95%
Current year+15.61%
1 week 49.97
Extreme 49.97
54.02
1 month 49.97
Extreme 49.97
56.95
Current year 39.71
Extreme 39.71
57.57
1 year 33.76
Extreme 33.755
57.57
3 years 18.64
Extreme 18.64
57.57
5 years 14.87
Extreme 14.87
57.57
10 years 10.04
Extreme 10.04
57.57
Manager TitleAgeSince
Chief Executive Officer 65 22/07/2010
Director of Finance/CFO 58 15/07/2015
Chief Operating Officer 63 01/02/2016
Director TitleAgeSince
Director/Board Member 70 01/02/2004
Director/Board Member 82 01/08/2004
Chairman 77 01/01/1998
Date Insider Type Main position Quantity % Market Cap.
10/8/26 Sell

Director

-9,812 0.0039%
27/5/26 Free

Director

8,367 0.0033%
26/2/26 Free

General Counsel

23,119 0.0086%
Change 5-day change 1-year change 3-year change Capi.($)
+0.24%-6.29%+31.71%+135.56% 12.54B
-1.90%+11.59%+62.29%+102.60% 71.56B
-3.21%-4.32%+31.19%+59.75% 54.43B
-2.72%-6.27%-3.81%+451.05% 27.59B
-1.27%+9.09%+46.56%+4.13% 23.91B
-0.59%-2.17%-18.69%-14.71% 23.14B
+0.10%+1.40%+38.98%-20.04% 18.65B
+3.81%+16.28%+270.78%+488.06% 18.64B
-0.95%+2.46%+24.40%+574.22% 16.01B
+0.16%-0.57%+36.56%+192.40% 11.72B
Average -0.62%+2.61%+52.00%+197.30% 27.82B
Weighted average by Cap. -1.31%+1.62%+49.33%+160.57%

Financials

2026 *2027 *
Net sales 2.55B 2.2B 2.07B 1.88B 3.54B 244B 3.6B 24.27B 9.49B 122B 9.58B 9.37B 406B 2.87B 2.48B 2.33B 2.12B 3.99B 275B 4.05B 27.34B 10.69B 138B 10.79B 10.56B 457B
Net income 814M 703M 661M 601M 1.13B 77.88B 1.15B 7.75B 3.03B 39B 3.06B 2.99B 130B 963M 832M 782M 711M 1.34B 92.11B 1.36B 9.16B 3.58B 46.12B 3.62B 3.54B 153B
Net Debt -744M -643M -604M -550M -1.03B -71.19B -1.05B -7.08B -2.77B -35.65B -2.8B -2.73B -118B -1.62B -1.4B -1.32B -1.2B -2.25B -155B -2.29B -15.43B -6.03B -77.7B -6.09B -5.96B -258B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
15/08/26 USD 50.63 +0.04% 519,779
13/08/26 USD 50.61 +0.46% 1,948,740
12/08/26 USD 50.38 -1.85% 2,938,705
11/08/26 USD 51.33 -3.08% 2,038,685
10/08/26 USD 52.96 -2.05% 3,349,673
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
50.61USD
Average target price
52.94USD
Spread / Average Target
+4.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock